RU2013153898A - Новые гексагидроциклопентапирролоны, гексагидропирролопирролоны, октагидропирролопиридиноны и октагидропиридиноны - Google Patents
Новые гексагидроциклопентапирролоны, гексагидропирролопирролоны, октагидропирролопиридиноны и октагидропиридиноны Download PDFInfo
- Publication number
- RU2013153898A RU2013153898A RU2013153898/04A RU2013153898A RU2013153898A RU 2013153898 A RU2013153898 A RU 2013153898A RU 2013153898/04 A RU2013153898/04 A RU 2013153898/04A RU 2013153898 A RU2013153898 A RU 2013153898A RU 2013153898 A RU2013153898 A RU 2013153898A
- Authority
- RU
- Russia
- Prior art keywords
- compound according
- phenyl
- substituted
- octahydropyrrolo
- trifluoromethoxyphenyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims abstract 44
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 24
- 125000000217 alkyl group Chemical group 0.000 claims abstract 18
- 125000003884 phenylalkyl group Chemical group 0.000 claims abstract 15
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 10
- 125000004438 haloalkoxy group Chemical group 0.000 claims abstract 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 9
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 8
- 125000001188 haloalkyl group Chemical group 0.000 claims abstract 8
- 229910052736 halogen Inorganic materials 0.000 claims abstract 8
- 150000002367 halogens Chemical class 0.000 claims abstract 8
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims abstract 8
- 125000005359 phenoxyalkyl group Chemical group 0.000 claims abstract 8
- 125000001424 substituent group Chemical group 0.000 claims abstract 8
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims abstract 7
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims abstract 4
- 125000004994 halo alkoxy alkyl group Chemical group 0.000 claims abstract 4
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims abstract 4
- 230000002265 prevention Effects 0.000 claims 23
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 17
- 206010012601 diabetes mellitus Diseases 0.000 claims 12
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- 201000001320 Atherosclerosis Diseases 0.000 claims 8
- 208000024172 Cardiovascular disease Diseases 0.000 claims 8
- 208000032928 Dyslipidaemia Diseases 0.000 claims 8
- 206010061218 Inflammation Diseases 0.000 claims 8
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 8
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 8
- 208000008589 Obesity Diseases 0.000 claims 8
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 8
- 230000004064 dysfunction Effects 0.000 claims 8
- 230000004054 inflammatory process Effects 0.000 claims 8
- 230000002107 myocardial effect Effects 0.000 claims 8
- 235000020824 obesity Nutrition 0.000 claims 8
- 230000001476 alcoholic effect Effects 0.000 claims 7
- 230000007850 degeneration Effects 0.000 claims 7
- 210000004185 liver Anatomy 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 125000004076 pyridyl group Chemical group 0.000 claims 5
- -1 roksigruppa Chemical group 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 4
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- OOPXPUHSUWIQHN-PBHICJAKSA-N (3ar,7as)-5-[4-(2,2,2-trifluoroethoxy)phenyl]-2-[2-(trifluoromethoxy)phenyl]sulfonyl-1,3,3a,6,7,7a-hexahydropyrrolo[3,4-c]pyridin-4-one Chemical compound C1=CC(OCC(F)(F)F)=CC=C1N1C(=O)[C@H]2CN(S(=O)(=O)C=3C(=CC=CC=3)OC(F)(F)F)C[C@H]2CC1 OOPXPUHSUWIQHN-PBHICJAKSA-N 0.000 claims 2
- ICURKDZAOKAZKG-OWQGQXMQSA-N (3as,5s,6ar)-5-(butoxymethyl)-5-hydroxy-2-[4-(trifluoromethoxy)phenyl]-3a,4,6,6a-tetrahydro-1h-cyclopenta[c]pyrrol-3-one Chemical compound C([C@@H]1C[C@@](C[C@@H]1C1=O)(O)COCCCC)N1C1=CC=C(OC(F)(F)F)C=C1 ICURKDZAOKAZKG-OWQGQXMQSA-N 0.000 claims 2
- RUZIVNMLRPKBGI-KUBVQFIISA-N (3as,7ar)-1-(2-phenylacetyl)-5-[4-(trifluoromethoxy)phenyl]-2,3,3a,6,7,7a-hexahydro-1h-pyrrolo[3,4-c]pyridin-4-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1N1C(=O)[C@H](CNC2C(=O)CC=3C=CC=CC=3)[C@H]2CC1 RUZIVNMLRPKBGI-KUBVQFIISA-N 0.000 claims 2
- IOHFWOZJENTFLA-XJKSGUPXSA-N (3as,7ar)-2-(2-chlorophenyl)sulfonyl-5-[4-(trifluoromethoxy)phenyl]-1,3,3a,6,7,7a-hexahydropyrrolo[3,4-c]pyridin-4-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1N1C(=O)[C@@H]2CN(S(=O)(=O)C=3C(=CC=CC=3)Cl)C[C@@H]2CC1 IOHFWOZJENTFLA-XJKSGUPXSA-N 0.000 claims 2
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 2
- 125000004863 4-trifluoromethoxyphenyl group Chemical group [H]C1=C([H])C(OC(F)(F)F)=C([H])C([H])=C1* 0.000 claims 2
- SDRXORFVMCHESD-CHEUHSMRSA-N (3ar,7as)-1-(2-phenylacetyl)-5-[4-(2,2,2-trifluoroethoxy)phenyl]-2,3,3a,6,7,7a-hexahydro-1h-pyrrolo[3,4-c]pyridin-4-one Chemical compound C1=CC(OCC(F)(F)F)=CC=C1N1C(=O)[C@@H](CNC2C(=O)CC=3C=CC=CC=3)[C@@H]2CC1 SDRXORFVMCHESD-CHEUHSMRSA-N 0.000 claims 1
- JWCAWYZVCBQCHU-PBHICJAKSA-N (3ar,7as)-2-(2-chlorophenyl)sulfonyl-5-[4-(2,2,2-trifluoroethoxy)phenyl]-1,3,3a,6,7,7a-hexahydropyrrolo[3,4-c]pyridin-4-one Chemical compound C1=CC(OCC(F)(F)F)=CC=C1N1C(=O)[C@H]2CN(S(=O)(=O)C=3C(=CC=CC=3)Cl)C[C@H]2CC1 JWCAWYZVCBQCHU-PBHICJAKSA-N 0.000 claims 1
- URZPTRWITOLAHH-CJNGLKHVSA-N (3ar,7as)-2-(2-chloropyridin-3-yl)sulfonyl-5-[4-(2,2,2-trifluoroethoxy)phenyl]-1,3,3a,6,7,7a-hexahydropyrrolo[3,4-c]pyridin-4-one Chemical compound C1=CC(OCC(F)(F)F)=CC=C1N1C(=O)[C@H]2CN(S(=O)(=O)C=3C(=NC=CC=3)Cl)C[C@H]2CC1 URZPTRWITOLAHH-CJNGLKHVSA-N 0.000 claims 1
- UTIMXNSQVSYIOG-PBHICJAKSA-N (3ar,7as)-2-(2-hydroxyphenyl)-5-[4-(2,2,2-trifluoroethoxy)phenyl]-1,3,3a,6,7,7a-hexahydropyrrolo[3,4-c]pyridin-4-one Chemical compound OC1=CC=CC=C1N1C[C@@H]2C(=O)N(C=3C=CC(OCC(F)(F)F)=CC=3)CC[C@@H]2C1 UTIMXNSQVSYIOG-PBHICJAKSA-N 0.000 claims 1
- TUTZPAJFLXAIQH-PBHICJAKSA-N (3ar,7as)-2-(3,3-dimethylbutanoyl)-5-[4-(2,2,2-trifluoroethoxy)phenyl]-1,3,3a,6,7,7a-hexahydropyrrolo[3,4-c]pyridin-4-one Chemical compound C([C@@H]1CN(C[C@@H]1C1=O)C(=O)CC(C)(C)C)CN1C1=CC=C(OCC(F)(F)F)C=C1 TUTZPAJFLXAIQH-PBHICJAKSA-N 0.000 claims 1
- QLGSFDRAOBTLSJ-BEFAXECRSA-N (3ar,7as)-2-(benzenesulfonyl)-5-[4-(2,2,2-trifluoroethoxy)phenyl]-1,3,3a,6,7,7a-hexahydropyrrolo[3,4-c]pyridin-4-one Chemical compound C1=CC(OCC(F)(F)F)=CC=C1N1C(=O)[C@H]2CN(S(=O)(=O)C=3C=CC=CC=3)C[C@H]2CC1 QLGSFDRAOBTLSJ-BEFAXECRSA-N 0.000 claims 1
- TZYWCWPNWKEQCG-ANEWXZNUSA-N (3ar,7as)-2-[2-(2,4-dichlorophenyl)-2-hydroxyethyl]-5-[4-(2,2,2-trifluoroethoxy)phenyl]-1,3,3a,6,7,7a-hexahydropyrrolo[3,4-c]pyridin-4-one Chemical compound C([C@@H]1CN(C[C@@H]1C1=O)CC(O)C=2C(=CC(Cl)=CC=2)Cl)CN1C1=CC=C(OCC(F)(F)F)C=C1 TZYWCWPNWKEQCG-ANEWXZNUSA-N 0.000 claims 1
- BWVIKPJQQKIUGB-PBHICJAKSA-N (3ar,7as)-5-[4-(2,2,2-trifluoroethoxy)phenyl]-2-[2-(trifluoromethyl)phenyl]sulfonyl-1,3,3a,6,7,7a-hexahydropyrrolo[3,4-c]pyridin-4-one Chemical compound C1=CC(OCC(F)(F)F)=CC=C1N1C(=O)[C@H]2CN(S(=O)(=O)C=3C(=CC=CC=3)C(F)(F)F)C[C@H]2CC1 BWVIKPJQQKIUGB-PBHICJAKSA-N 0.000 claims 1
- ZOSXIEYYQRCFQH-XEGUGMAKSA-N (3as,5s,6ar)-5-hydroxy-5-(2,2,2-trifluoroethoxymethyl)-2-[4-(trifluoromethoxy)phenyl]-3a,4,6,6a-tetrahydro-1h-cyclopenta[c]pyrrol-3-one Chemical compound C([C@@H]1C[C@](C[C@@H]1C1=O)(COCC(F)(F)F)O)N1C1=CC=C(OC(F)(F)F)C=C1 ZOSXIEYYQRCFQH-XEGUGMAKSA-N 0.000 claims 1
- FWMIDUCEURWGLJ-DCPHZVHLSA-N (3as,5s,6ar)-5-hydroxy-5-(phenoxymethyl)-2-[4-(trifluoromethoxy)phenyl]-3a,4,6,6a-tetrahydro-1h-cyclopenta[c]pyrrol-3-one Chemical compound C([C@@]1(O)C[C@@H]2C(=O)N(C[C@@H]2C1)C=1C=CC(OC(F)(F)F)=CC=1)OC1=CC=CC=C1 FWMIDUCEURWGLJ-DCPHZVHLSA-N 0.000 claims 1
- UQTFGVGNOYPZBT-NUTKFTJISA-N (3as,5s,6ar)-5-hydroxy-5-(propoxymethyl)-2-[4-(trifluoromethoxy)phenyl]-3a,4,6,6a-tetrahydro-1h-cyclopenta[c]pyrrol-3-one Chemical compound C([C@@H]1C[C@@](C[C@@H]1C1=O)(O)COCCC)N1C1=CC=C(OC(F)(F)F)C=C1 UQTFGVGNOYPZBT-NUTKFTJISA-N 0.000 claims 1
- JQQBOTWLJXCTBZ-KEXXGOCASA-N (3as,6ar)-5-(anilinomethyl)-5-hydroxy-2-[4-(trifluoromethoxy)phenyl]-3a,4,6,6a-tetrahydro-1h-cyclopenta[c]pyrrol-3-one Chemical compound C([C@@H]1C(=O)N(C[C@@H]1C1)C=2C=CC(OC(F)(F)F)=CC=2)C1(O)CNC1=CC=CC=C1 JQQBOTWLJXCTBZ-KEXXGOCASA-N 0.000 claims 1
- SNVFIFXXEAAXLK-XPFLZZBLSA-N (3as,6ar)-5-hydroxy-5-propyl-2-[4-(trifluoromethoxy)phenyl]-3a,4,6,6a-tetrahydro-1h-cyclopenta[c]pyrrol-3-one Chemical compound C([C@@H]1CC(C[C@@H]1C1=O)(O)CCC)N1C1=CC=C(OC(F)(F)F)C=C1 SNVFIFXXEAAXLK-XPFLZZBLSA-N 0.000 claims 1
- UTWATDQGGKALAL-SUMWQHHRSA-N (3as,7ar)-2-(2-chlorobenzoyl)-5-[4-(trifluoromethoxy)phenyl]-1,3,3a,6,7,7a-hexahydropyrrolo[3,4-c]pyridin-4-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1N1C(=O)[C@@H]2CN(C(=O)C=3C(=CC=CC=3)Cl)C[C@@H]2CC1 UTWATDQGGKALAL-SUMWQHHRSA-N 0.000 claims 1
- YXAQHOMOMXWBST-XJKSGUPXSA-N (3as,7ar)-2-(2-methylpropylsulfonyl)-5-[4-(trifluoromethoxy)phenyl]-1,3,3a,6,7,7a-hexahydropyrrolo[3,4-c]pyridin-4-one Chemical compound C([C@H]1CN(C[C@H]1C1=O)S(=O)(=O)CC(C)C)CN1C1=CC=C(OC(F)(F)F)C=C1 YXAQHOMOMXWBST-XJKSGUPXSA-N 0.000 claims 1
- FIADIBYFRWITEN-XJKSGUPXSA-N (3as,7ar)-2-(3-methylbutanoyl)-5-[4-(trifluoromethoxy)phenyl]-1,3,3a,6,7,7a-hexahydropyrrolo[3,4-c]pyridin-4-one Chemical compound C([C@H]1CN(C[C@H]1C1=O)C(=O)CC(C)C)CN1C1=CC=C(OC(F)(F)F)C=C1 FIADIBYFRWITEN-XJKSGUPXSA-N 0.000 claims 1
- TWMYWSDGOVHDKS-WMLDXEAASA-N (3as,7ar)-2-(3-methylbutylsulfonyl)-5-[4-(trifluoromethoxy)phenyl]-1,3,3a,6,7,7a-hexahydropyrrolo[3,4-c]pyridin-4-one Chemical compound C([C@H]1CN(C[C@H]1C1=O)S(=O)(=O)CCC(C)C)CN1C1=CC=C(OC(F)(F)F)C=C1 TWMYWSDGOVHDKS-WMLDXEAASA-N 0.000 claims 1
- MFAMMXPGEWSZTR-KBXCAEBGSA-N (3as,7ar)-2-(4-fluorobenzoyl)-5-[4-(trifluoromethoxy)phenyl]-1,3,3a,6,7,7a-hexahydropyrrolo[3,4-c]pyridin-4-one Chemical compound C1=CC(F)=CC=C1C(=O)N1C[C@H]2C(=O)N(C=3C=CC(OC(F)(F)F)=CC=3)CC[C@H]2C1 MFAMMXPGEWSZTR-KBXCAEBGSA-N 0.000 claims 1
- WPSQOKLLQVOTBZ-SCLBCKFNSA-N (3as,7ar)-2-(4-fluorophenyl)sulfonyl-5-[4-(trifluoromethoxy)phenyl]-1,3,3a,6,7,7a-hexahydropyrrolo[3,4-c]pyridin-4-one Chemical compound C1=CC(F)=CC=C1S(=O)(=O)N1C[C@H]2C(=O)N(C=3C=CC(OC(F)(F)F)=CC=3)CC[C@H]2C1 WPSQOKLLQVOTBZ-SCLBCKFNSA-N 0.000 claims 1
- UVQXTGZXMGDYMH-GHTZIAJQSA-N (3as,7ar)-2-(4-propan-2-ylbenzoyl)-5-[4-(trifluoromethoxy)phenyl]-1,3,3a,6,7,7a-hexahydropyrrolo[3,4-c]pyridin-4-one Chemical compound C1=CC(C(C)C)=CC=C1C(=O)N1C[C@H]2C(=O)N(C=3C=CC(OC(F)(F)F)=CC=3)CC[C@H]2C1 UVQXTGZXMGDYMH-GHTZIAJQSA-N 0.000 claims 1
- DXVHIIDHQSBIDF-HNAYVOBHSA-N (3as,7ar)-2-[(4-fluorophenyl)methyl]-5-[4-(trifluoromethoxy)phenyl]-1,3,3a,6,7,7a-hexahydropyrrolo[3,4-c]pyridin-4-one Chemical compound C1=CC(F)=CC=C1CN1C[C@H]2C(=O)N(C=3C=CC(OC(F)(F)F)=CC=3)CC[C@H]2C1 DXVHIIDHQSBIDF-HNAYVOBHSA-N 0.000 claims 1
- ABDCELHRYJDOPX-QFBILLFUSA-N (3as,7ar)-2-benzylsulfonyl-5-[4-(trifluoromethoxy)phenyl]-1,3,3a,6,7,7a-hexahydropyrrolo[3,4-c]pyridin-4-one Chemical compound C1=CC(OC(F)(F)F)=CC=C1N1C(=O)[C@@H]2CN(S(=O)(=O)CC=3C=CC=CC=3)C[C@@H]2CC1 ABDCELHRYJDOPX-QFBILLFUSA-N 0.000 claims 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- GCNTZFIIOFTKIY-UHFFFAOYSA-N 4-hydroxypyridine Chemical compound OC1=CC=NC=C1 GCNTZFIIOFTKIY-UHFFFAOYSA-N 0.000 claims 1
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims 1
- FUZWCQZNXDIYNW-LOCPCMAASA-N CCC(C=C1)=CC=C1N(C[C@@H](C1)[C@H]2CN1C(O)=O)C2=O.NC(C=C1)=CC=C1OC(F)(F)F Chemical compound CCC(C=C1)=CC=C1N(C[C@@H](C1)[C@H]2CN1C(O)=O)C2=O.NC(C=C1)=CC=C1OC(F)(F)F FUZWCQZNXDIYNW-LOCPCMAASA-N 0.000 claims 1
- 102000000019 Sterol Esterase Human genes 0.000 claims 1
- 108010055297 Sterol Esterase Proteins 0.000 claims 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- NYMDZLNOQPHCMN-CJNGLKHVSA-N tert-butyl (3ar,7as)-4-oxo-5-[4-(2,2,2-trifluoroethoxy)phenyl]-1,3,3a,6,7,7a-hexahydropyrrolo[3,4-c]pyridine-2-carboxylate Chemical compound C([C@@H]1CN(C[C@@H]1C1=O)C(=O)OC(C)(C)C)CN1C1=CC=C(OCC(F)(F)F)C=C1 NYMDZLNOQPHCMN-CJNGLKHVSA-N 0.000 claims 1
- LMSUQMJAMATPBV-DOMZBBRYSA-N tert-butyl (3ar,7as)-4-oxo-5-[4-(trifluoromethoxy)phenyl]-1,3,3a,6,7,7a-hexahydropyrrolo[3,4-c]pyridine-2-carboxylate Chemical compound C([C@@H]1CN(C[C@@H]1C1=O)C(=O)OC(C)(C)C)CN1C1=CC=C(OC(F)(F)F)C=C1 LMSUQMJAMATPBV-DOMZBBRYSA-N 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11166437.1 | 2011-05-17 | ||
| EP11166437 | 2011-05-17 | ||
| PCT/EP2012/058852 WO2012156339A1 (en) | 2011-05-17 | 2012-05-14 | New hexahydrocyclopentapyrrolone, hexahydropyrrolopyrrolone, octahydropyrrolopyridinone and octahydropyridinone compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013153898A true RU2013153898A (ru) | 2015-06-27 |
Family
ID=46124329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013153898/04A RU2013153898A (ru) | 2011-05-17 | 2012-05-14 | Новые гексагидроциклопентапирролоны, гексагидропирролопирролоны, октагидропирролопиридиноны и октагидропиридиноны |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8501768B2 (https=) |
| EP (1) | EP2709984B1 (https=) |
| JP (1) | JP2014513703A (https=) |
| KR (1) | KR20140042814A (https=) |
| CN (1) | CN103562180B (https=) |
| BR (1) | BR112013028368A2 (https=) |
| CA (1) | CA2832334A1 (https=) |
| ES (1) | ES2537591T3 (https=) |
| MX (1) | MX346980B (https=) |
| RU (1) | RU2013153898A (https=) |
| WO (1) | WO2012156339A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8497288B2 (en) * | 2011-05-09 | 2013-07-30 | Hoffmann-La Roche Inc. | Hexahydropyrroloimidazolone compounds |
| WO2015048507A1 (en) | 2013-09-26 | 2015-04-02 | Mnemosyne Pharmaceuticals, Inc. | Selective octahydro-cyclopenta[c] pyrrole negative modulators of nr2b |
| JO3579B1 (ar) | 2014-09-26 | 2020-07-05 | Luc Therapeutics Inc | مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول |
| CA2979534A1 (en) * | 2015-03-13 | 2016-09-22 | Abbvie Inc. | (indazol-4-yl)hexahydropyrrolopyrrolones and method of use |
| CN110430890B (zh) | 2016-11-10 | 2024-09-10 | 科乐斯疗法公司 | 激活素受体iia型变体及其使用方法 |
| IL320014A (en) | 2018-01-12 | 2025-06-01 | Keros Therapeutics Inc | Activin receptor type iib variants and methods of use thereof |
| WO2021189010A1 (en) | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| IL296394A (en) | 2020-03-20 | 2022-11-01 | Keros Therapeutics Inc | Type ii activin receptor chimeras and methods of using them |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19942354A1 (de) * | 1999-09-04 | 2001-03-08 | Aventis Pharma Gmbh | Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one, ihre Herstellung und Verwendung in Arzneimitteln |
| RU2281283C2 (ru) * | 2000-03-07 | 2006-08-10 | Санофи-Авентис Дойчланд Гмбх | Замещенные 3-фенил-5-алкокси-1,3,4-оксадиазол-2-оны и их применение для ингибирования гормоночувствительной липазы |
| CA2436943A1 (en) * | 2000-12-01 | 2003-06-06 | Cerep Sa | Hydantoin compounds useful as anti-inflammatory agents |
| CN101115741A (zh) * | 2005-02-15 | 2008-01-30 | 诺和诺德公司 | 3,4-二氢-1h-异喹啉-2-羧酸5-氨基吡啶-2-基酯 |
| CN101336243A (zh) * | 2005-12-05 | 2008-12-31 | 因塞特公司 | 内酰胺化合物和其使用方法 |
| ATE471311T1 (de) * | 2006-04-25 | 2010-07-15 | Lilly Co Eli | Inhibitoren von11-beta- hydroxysteroiddehydrogenase 1 |
| AU2008248996A1 (en) * | 2007-04-27 | 2008-11-13 | Sanofi-Aventis | 2 -heteroaryl- pyrrolo [3, 4-C] pyrrole derivatives and their use as SCD inhibitors |
| WO2010108268A1 (en) | 2009-03-23 | 2010-09-30 | Merck Frosst Canada Ltd. | Heterocyclic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| ES2585806T3 (es) * | 2009-10-23 | 2016-10-10 | Janssen Pharmaceutica N.V. | Octahidropirrolo [3,4-c] pirroles disustituidos como moduladores de receptores de orexina |
| UY33227A (es) * | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
-
2012
- 2012-05-04 US US13/463,863 patent/US8501768B2/en not_active Expired - Fee Related
- 2012-05-14 MX MX2013011628A patent/MX346980B/es active IP Right Grant
- 2012-05-14 JP JP2014510758A patent/JP2014513703A/ja active Pending
- 2012-05-14 KR KR1020137033414A patent/KR20140042814A/ko not_active Withdrawn
- 2012-05-14 WO PCT/EP2012/058852 patent/WO2012156339A1/en not_active Ceased
- 2012-05-14 EP EP12721814.7A patent/EP2709984B1/en not_active Not-in-force
- 2012-05-14 CA CA2832334A patent/CA2832334A1/en not_active Abandoned
- 2012-05-14 RU RU2013153898/04A patent/RU2013153898A/ru not_active Application Discontinuation
- 2012-05-14 ES ES12721814.7T patent/ES2537591T3/es active Active
- 2012-05-14 CN CN201280023662.XA patent/CN103562180B/zh not_active Expired - Fee Related
- 2012-05-14 BR BR112013028368A patent/BR112013028368A2/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012156339A1 (en) | 2012-11-22 |
| US8501768B2 (en) | 2013-08-06 |
| BR112013028368A2 (pt) | 2017-01-24 |
| ES2537591T3 (es) | 2015-06-09 |
| US20120295934A1 (en) | 2012-11-22 |
| HK1191942A1 (zh) | 2014-08-08 |
| CN103562180A (zh) | 2014-02-05 |
| CN103562180B (zh) | 2016-04-20 |
| EP2709984B1 (en) | 2015-03-18 |
| CA2832334A1 (en) | 2012-11-22 |
| MX2013011628A (es) | 2013-10-25 |
| MX346980B (es) | 2017-04-07 |
| JP2014513703A (ja) | 2014-06-05 |
| KR20140042814A (ko) | 2014-04-07 |
| EP2709984A1 (en) | 2014-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013153898A (ru) | Новые гексагидроциклопентапирролоны, гексагидропирролопирролоны, октагидропирролопиридиноны и октагидропиридиноны | |
| RU2650895C2 (ru) | Соединения замещенных пиразолонов и способы использования | |
| RU2016127621A (ru) | Производные имидазопиридина в качестве модуляторов активности tnf | |
| WO2019067843A1 (en) | PYRAZOLO [3,4-B] PYRAZINE DERIVATIVES AS INHIBITORS OF PHOSPHATASE SHP2 | |
| US12157732B2 (en) | eIF4E inhibitors and uses thereof | |
| RU2016127441A (ru) | Конденсированные бициклические гетероароматические производные в качестве модуляторов активности tnf | |
| AU2011270719B2 (en) | Niacin mimetics, and methods of use thereof | |
| RU2016126658A (ru) | Конденсированные производные имидазола и пиразола в качестве модуляторов активности tnf | |
| JP2013533279A5 (https=) | ||
| RU2016126659A (ru) | Производные тетрагидробензимидазола в качестве модуляторов активности tnf | |
| RU2013153529A (ru) | Новые соединения и композиции для ингибирования nampt | |
| RU2016127227A (ru) | Производные имидазопиридина в качестве модуляторов активности tnf | |
| RU2016126970A (ru) | Производные имидазопиридазина в качестве модуляторов активности tnf | |
| RU2016126656A (ru) | Производные тетрагидроимидазопиридина в качестве модуляторов активновти tnf | |
| JP2014513703A5 (https=) | ||
| RU2016127439A (ru) | Производные имидазопиридина в качестве модуляторов активности tnf | |
| JP2014524413A (ja) | 置換３−（ビフェニル−３−イル）−４−ヒドロキシ−８−メトキシ−１−アザスピロ［４．５］デセ−３−エン−２−オン類 | |
| JP2026053473A (ja) | 癌または炎症性疾患の治療のためのヘテロ二環式カルボキシ酸 | |
| JP2009514802A5 (https=) | ||
| RU2016127440A (ru) | Производные тетрагидроимидазопиридина в качестве модуляторов активности tnf | |
| JP2020533345A5 (https=) | ||
| CA2422064A1 (en) | Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist | |
| RU2015140600A (ru) | Производные мочевины и их применение в качестве ингибиторов белка, связывающего жирные кислоты | |
| TW200817378A (en) | Compositions and methods for treating or preventing glaucoma or progression thereof | |
| MX2007006744A (es) | Derivados de hidantoina utiles como inhibidores de metaloproteinasa. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20180802 |